Phase II Study of Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer

Trial Profile

Phase II Study of Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Fluorouracil; Irinotecan; Oxaliplatin
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Oct 2017 Status changed from recruiting to discontinued.
    • 10 Jun 2017 Biomarkers information updated
    • 03 Dec 2014 Planned End Date changed from 1 Sep 2019 to 1 Dec 2019 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top